Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1985 1
2003 1
2005 2
2006 1
2007 1
2008 1
2009 3
2010 7
2011 5
2012 3
2013 3
2014 1
2016 2
2017 2
2020 3
2021 7
2022 6
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM, Lacarra B, Afolabi MO, Ale BM, Baiden F, Bétard C, Foster J, Hamzé B, Schwimmer C, Manno D, D'Ortenzio E, Ishola D, Keita CM, Keshinro B, Njie Y, van Dijck W, Gaddah A, Anumendem D, Lowe B, Vatrinet R, Lawal BJ, Otieno GT, Samai M, Deen GF, Swaray IB, Kamara AB, Kamara MM, Diagne MA, Kowuor D, McLean C, Leigh B, Beavogui AH, Leyssen M, Luhn K, Robinson C, Douoguih M, Greenwood B, Thiébaut R, Watson-Jones D; EBOVAC-3/EBL2005 Study Team. Choi EM, et al. Among authors: leyssen m. Lancet Glob Health. 2023 Nov;11(11):e1743-e1752. doi: 10.1016/S2214-109X(23)00410-2. Lancet Glob Health. 2023. PMID: 37858585 Free article. Clinical Trial.
A fruitfly's guide to keeping the brain wired.
Leyssen M, Hassan BA. Leyssen M, et al. EMBO Rep. 2007 Jan;8(1):46-50. doi: 10.1038/sj.embor.7400869. EMBO Rep. 2007. PMID: 17203102 Free PMC article. Review.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, van Heesbeen R, Schuitemaker H, Douoguih M, Evans E, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Custers J, et al. Among authors: leyssen m. Vaccine. 2021 May 21;39(22):3081-3101. doi: 10.1016/j.vaccine.2020.09.018. Epub 2020 Oct 3. Vaccine. 2021. PMID: 33676782 Free PMC article. Review.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop JN, Roozendaal R, Van Effelterre T, Gaddah A, Van Roey GA, Solforosi L, Zahn R, Callendret B, Hendriks J, Luhn K, Douoguih M, Schuitemaker H, Van Hoof J. Bockstal V, et al. Among authors: leyssen m. NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z. NPJ Vaccines. 2022. PMID: 36450746 Free PMC article.
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Salisch NC, Stephenson KE, Williams K, Cox F, van der Fits L, Heerwegh D, Truyers C, Habets MN, Kanjilal DG, Larocca RA, Abbink P, Liu J, Peter L, Fierro C, De La Barrera RA, Modjarrad K, Zahn RC, Hendriks J, Cahill CP, Leyssen M, Douoguih M, van Hoof J, Schuitemaker H, Barouch DH. Salisch NC, et al. Among authors: leyssen m. Ann Intern Med. 2021 May;174(5):585-594. doi: 10.7326/M20-5306. Epub 2021 Feb 16. Ann Intern Med. 2021. PMID: 33587687 Clinical Trial.
Interaction of depth probes and style of depiction.
van Doorn AJ, Koenderink JJ, Leyssen MH, Wagemans J. van Doorn AJ, et al. Among authors: leyssen mh. Iperception. 2012;3(8):528-40. doi: 10.1068/i0500. Epub 2012 Aug 17. Iperception. 2012. PMID: 23145306 Free PMC article.
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Watson-Jones D, Kavunga-Membo H, Grais RF, Ahuka S, Roberts N, Edmunds WJ, Choi EM, Roberts CH, Edwards T, Camacho A, Lees S, Leyssen M, Spiessens B, Luhn K, Douoguih M, Hatchett R, Bausch DG, Muyembe JJ; DRC-EB-001 protocol writing team. Watson-Jones D, et al. Among authors: leyssen m. BMJ Open. 2022 Mar 8;12(3):e055596. doi: 10.1136/bmjopen-2021-055596. BMJ Open. 2022. PMID: 35260458 Free PMC article.
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Karita E, Nyombayire J, Ingabire R, Mazzei A, Sharkey T, Mukamuyango J, Allen S, Tichacek A, Parker R, Priddy F, Sayinzoga F, Nsanzimana S, Robinson C, Katwere M, Anumendem D, Leyssen M, Schaefer M, Wall KM. Karita E, et al. Among authors: leyssen m. Trials. 2022 Jun 20;23(1):513. doi: 10.1186/s13063-022-06360-3. Trials. 2022. PMID: 35725488 Free PMC article.
Mutations in the intellectual disability gene Ube2a cause neuronal dysfunction and impair parkin-dependent mitophagy.
Haddad DM, Vilain S, Vos M, Esposito G, Matta S, Kalscheuer VM, Craessaerts K, Leyssen M, Nascimento RM, Vianna-Morgante AM, De Strooper B, Van Esch H, Morais VA, Verstreken P. Haddad DM, et al. Among authors: leyssen m. Mol Cell. 2013 Jun 27;50(6):831-43. doi: 10.1016/j.molcel.2013.04.012. Epub 2013 May 16. Mol Cell. 2013. PMID: 23685073 Free article.
43 results